Sign inJoin waitlistJoin the waitlist

Cora N. Sternberg

Clinical Director of the Englander Institute for Precision Medicine · Weill Cornell Medicine

Credentials: ·

History

Englander Institute for Precision Medicine Center · Weill Cornell Medicine
Present

Research

Increased survival with enzalutamide in prostate cancer after chemotherapy
New England Journal of Medicine · 2012 · 3,725 citations
Abiraterone and increased survival in metastatic prostate cancer
New England Journal of Medicine · 2011 · 3,621 citations
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
New England Journal of Medicine · 2017 · 2,802 citations

HS
Howard Scher
58 papers
Joaquim Bellmunt
58 papers
Maha Hussain
42 papers
Daniel Petrylak
38 papers
Andrew Armstrong
32 papers
GS
Guru Sonpavde
32 papers
Scott Tagawa
31 papers
Neeraj Agarwal
30 papers
TB
Tomasz Beer
29 papers
NS
Neal Shore
27 papers
CH
Celestia Higano
26 papers
Matthew Galsky
26 papers

Grants

The Joint WCM-NYGC Center for Functional and Clinical Interpretation of Tumor Profiles
National Cancer Institute · U24
PI · $2M · Weill Medical Coll of Cornell Univ
2021–2026

Clinical trials

Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers
Principal investigator · Withdrawn · Phase 1
Weill Medical College of Cornell University
2023–2028
TAK-700 in Castration Resistant Prostate Cancer
Principal investigator · Withdrawn · Phase 2
European Organisation for Research and Treatment of Cancer - EORTC
2014–2017
Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate
Study chair · Completed · Phase 2
European Organisation for Research and Treatment of Cancer - EORTC
2004
Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium
Study chair · Completed · Phase 3
European Organisation for Research and Treatment of Cancer - EORTC
2001–2014